Application of furazolidone in Helicobacter pylori infection eradication

IF 2.3 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Journal of Digestive Diseases Pub Date : 2024-04-16 DOI:10.1111/1751-2980.13265
Ying Ying Han, Ji Yan Li, Jia Lun Guan, Mei Liu, Pei Yuan Li
{"title":"Application of furazolidone in Helicobacter pylori infection eradication","authors":"Ying Ying Han,&nbsp;Ji Yan Li,&nbsp;Jia Lun Guan,&nbsp;Mei Liu,&nbsp;Pei Yuan Li","doi":"10.1111/1751-2980.13265","DOIUrl":null,"url":null,"abstract":"<p>Increasing antibiotic resistance is the primary reason for treatment failure of <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection. To enhance the eradication rate, minimize the development of secondary resistance, and alleviate the socioeconomic burden, it is crucial to select <i>H. pylori</i>-sensitive antibiotics carefully. Furazolidone has been used for <i>H. pylori</i> eradication in developing countries for decades due to its affordability and low resistance rate. Numerous studies have demonstrated that furazolidone-containing regimens are more efficacious than those containing other antibiotics, as both first- and second-line therapies, and are also well tolerated. However, utility of furazolidone is restricted or not optimal in certain countries due to its infrequent but potentially severe adverse effects. The decision to discontinue usage of furazolidone because of concerns regarding adverse effects may be misguided. Here we comprehensively reviewed the studies on furazolidone at different dosages and treatment durations for <i>H. pylori</i> eradication. Further research on the mechanisms of action and clinical trials of furazolidone are of great practical importance.</p>","PeriodicalId":15564,"journal":{"name":"Journal of Digestive Diseases","volume":"25 3","pages":"148-155"},"PeriodicalIF":2.3000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Digestive Diseases","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1751-2980.13265","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Increasing antibiotic resistance is the primary reason for treatment failure of Helicobacter pylori (H. pylori) infection. To enhance the eradication rate, minimize the development of secondary resistance, and alleviate the socioeconomic burden, it is crucial to select H. pylori-sensitive antibiotics carefully. Furazolidone has been used for H. pylori eradication in developing countries for decades due to its affordability and low resistance rate. Numerous studies have demonstrated that furazolidone-containing regimens are more efficacious than those containing other antibiotics, as both first- and second-line therapies, and are also well tolerated. However, utility of furazolidone is restricted or not optimal in certain countries due to its infrequent but potentially severe adverse effects. The decision to discontinue usage of furazolidone because of concerns regarding adverse effects may be misguided. Here we comprehensively reviewed the studies on furazolidone at different dosages and treatment durations for H. pylori eradication. Further research on the mechanisms of action and clinical trials of furazolidone are of great practical importance.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
呋喃唑酮在根除幽门螺旋杆菌感染中的应用
抗生素耐药性的增加是幽门螺旋杆菌(H. pylori)感染治疗失败的主要原因。为了提高根除率,减少二次耐药性的产生,减轻社会经济负担,谨慎选择对幽门螺杆菌敏感的抗生素至关重要。几十年来,呋喃唑酮因其价格低廉、耐药率低,一直被发展中国家用于根除幽门螺杆菌。大量研究表明,含有呋喃唑酮的治疗方案比含有其他抗生素的治疗方案更有效,无论是作为一线还是二线疗法,耐受性都很好。然而,在某些国家,呋喃唑酮的使用受到了限制,或者由于其不常见但潜在的严重不良反应而无法达到最佳效果。因担心不良反应而决定停用呋喃唑酮可能是错误的。在此,我们全面回顾了不同剂量和疗程的呋喃唑酮根除幽门螺杆菌的研究。对呋喃唑酮作用机制的进一步研究和临床试验具有重要的现实意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Digestive Diseases
Journal of Digestive Diseases 医学-胃肠肝病学
CiteScore
5.40
自引率
2.90%
发文量
81
审稿时长
6-12 weeks
期刊介绍: The Journal of Digestive Diseases is the official English-language journal of the Chinese Society of Gastroenterology. The journal is published twelve times per year and includes peer-reviewed original papers, review articles and commentaries concerned with research relating to the esophagus, stomach, small intestine, colon, liver, biliary tract and pancreas.
期刊最新文献
Immune Checkpoint Inhibitors Affect Post-Progression Survival of Specific Patient Subgroups With Advanced Hepatocellular Carcinoma: A Study Cohorts' Analysis. Ethnic Minority Disparities in the Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Representative Area of China. Association of Poor Sleep Quality With Adverse Outcomes in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Climate Sustainability as a Catalyst for Quality and Excellence in Gastrointestinal Endoscopy: A Narrative Review. Sarcopenia as a Risk Factor for Mortality in NAFLD: How Should We Diagnose It?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1